Your browser doesn't support javascript.
loading
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.
Fajgenbaum, David C; Langan, Ruth-Anne; Japp, Alberto Sada; Partridge, Helen L; Pierson, Sheila K; Singh, Amrit; Arenas, Daniel J; Ruth, Jason R; Nabel, Christopher S; Stone, Katie; Okumura, Mariko; Schwarer, Anthony; Jose, Fábio Freire; Hamerschlak, Nelson; Wertheim, Gerald B; Jordan, Michael B; Cohen, Adam D; Krymskaya, Vera; Rubenstein, Arthur; Betts, Michael R; Kambayashi, Taku; van Rhee, Frits; Uldrick, Thomas S.
Afiliación
  • Fajgenbaum DC; Department of Medicine and.
  • Langan RA; Department of Medicine and.
  • Japp AS; Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Partridge HL; Department of Medicine and.
  • Pierson SK; Department of Medicine and.
  • Singh A; Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, British Columbia, Canada.
  • Arenas DJ; Department of Medicine and.
  • Ruth JR; Castleman Disease Collaborative Network, Philadelphia, Pennsylvania, USA.
  • Nabel CS; Dana Farber Cancer Research Institute, Boston, Massachusetts, USA.
  • Stone K; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
  • Okumura M; Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Schwarer A; Department of Haematology and Oncology, Eastern Health Monash University Clinical School, Melbourne, Victoria, Australia.
  • Jose FF; Department of Rheumatology and.
  • Hamerschlak N; Department of Hematology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
  • Wertheim GB; Department of Pathology & Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Jordan MB; Division of Immunobiology, Department of Pediatrics, Cincinnati Children's Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Cohen AD; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Krymskaya V; Department of Medicine and.
  • Rubenstein A; Department of Medicine and.
  • Betts MR; Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Kambayashi T; Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • van Rhee F; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
  • Uldrick TS; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
J Clin Invest ; 129(10): 4451-4463, 2019 08 13.
Article en En | MEDLINE | ID: mdl-31408438
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Transducción de Señal / Enfermedad de Castleman / Interleucina-6 / Fosfatidilinositol 3-Quinasas / Sirolimus / Proteínas Proto-Oncogénicas c-akt / Serina-Treonina Quinasas TOR Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Invest Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Transducción de Señal / Enfermedad de Castleman / Interleucina-6 / Fosfatidilinositol 3-Quinasas / Sirolimus / Proteínas Proto-Oncogénicas c-akt / Serina-Treonina Quinasas TOR Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Invest Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos